The FDA last week approved Sanofi and Regeneron’s Dupixent for the treatment of atopic dermatitis in young children, aged between six months and five years, who have not responded to previously prescribed topical therapies. It will be the first biologic medicine available to this age group for this indication. In the atopic dermatitis market basket, Dupixent already holds covered or better status for 89% of all insured lives under the pharmacy benefit. About 38% of insured lives have preferred access to Dupixent with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 6/8/22